menu
    • menu

    Company profile for Harbour BioMed

    NEW Drugs in Dev: 13
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Harbour BioMed is a global clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics in oncology and immunological disease areas to address unmet patient needs. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions....
    Harbour BioMed is a global clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics in oncology and immunological disease areas to address unmet patient needs. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions. The Company’s proprietary antibody technology platform Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as a heavy chain only (HCAb) format.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Harbour BioMedUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    22 Strathmore Rd, Suite 355, Natick, MA 01760
    Telephone
    Telephone
    +1-617-6823679
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.harbourbiomed.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/harbour-biomed/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Harbour BioMed’s IND for HBM7004 Cleared by FDA
    Harbour BioMed’s IND for HBM7004 Cleared by FDA

    08 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/harbour-biomed-announces-us-fda-ind-clearance-for-hbm7004-for-the-treatment-of-advanced-solid-tumors-302766800.html

    PR NEWSWIRE
    08 May 2026
    Share Share
    Harbour Biomed Appoints Dr. Adam Zong As President
    Harbour Biomed Appoints Dr. Adam Zong As President

    16 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/harbour-biomed-appoints-dr-adam-zong-as-president-302744447.html

    PR NEWSWIRE
    16 Apr 2026
    Share Share
    Harbour Biomed Reveals 2025 Financials: Global Collaboration
    Harbour Biomed Reveals 2025 Financials: Global Collaboration

    30 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/harbour-biomed-reports-full-year-2025-financial-results-sustained-global-collaboration-underpins-long-term-growth-302728708.html

    PR NEWSWIRE
    30 Mar 2026
    Share Share
    Kelun-Biotech, Harbour Biomed Get NMPA Nod For SKB575/HBM7575
    Kelun-Biotech, Harbour Biomed Get NMPA Nod For SKB575/HBM7575

    10 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kelun-biotech-and-harbour-biomed-announce-nmpa-approval-of-ind-application-for-skb575hbm7575-for-the-treatment-of-atopic-dermatitis-302708065.html

    PR NEWSWIRE
    10 Mar 2026
    Share Share
    Harbour Sails With Solstice In $1.1B Biobucks Deal
    Harbour Sails With Solstice In $1.1B Biobucks Deal

    24 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/harbour-helps-form-new-biotech-licensing-anti-ctla-4-asset-11b-biobucks-deal

    FIERCE BIOTECH
    24 Feb 2026
    Share Share
    Harbour Biomed Announces Positive 2025 Profit Alert
    Harbour Biomed Announces Positive 2025 Profit Alert

    03 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/harbour-biomed-announces-positive-profit-alert-for-2025-annual-results-302678303.html

    PR NEWSWIRE
    03 Feb 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search